ExoXpert will operate the ExoPulse platform to serve demand from exosome developers for R&D-grade exosome vials as well as GMP manufacturing capabilities.
Singapore advanced therapy drug manufacturer secures $21mn growth capital funding to expand global genetic medicines design and manufacturing operations.